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Purpose: The primary use of autogenous arteriovenous access for chronic hemodialysis is recommended by the National
Kidney Foundation–Dialysis Outcomes Quality Initiative practice guidelines. We review the outcomes of basilic vein
transposition (BVT) to assess its value as a primary upper arm arteriovenous access option.
Methods: A retrospective review of 56 patients undergoing BVT was performed. Thirty patients were men; average age was
56 years. Etiology of end-stage renal disease, complications, and time to maturation were tabulated. Primary and
secondary patency rates were determined by using life table methods. Multivariate regression analysis was performed to
assess risk factors for fistula failure.
Results: Renal failure was associated with diabetes in 32 (57%) patients, and BVT was the primary access procedure in 22
(39%) patients. Perioperative complications occurred in 5 (9%) patients and included hematoma (n  3), myocardial
infarction (n 1), and death (n 1). The average time to maturation was 74 days (range, 12-265 days), and maturation
failure occurred in 21 (38%) patients. Logistic regression analysis showed that age older than 60 years was associated with
poorer maturation and patency rates. On an intent-to-treat basis, 1-year primary and secondary patencies were 35% and
47%, respectively, but only 18% and 28%, respectively, for age >60 years. Forty-two percent of failed BVT were
subsequently replaced with a prosthetic graft by using the same upper arm vessels.
Conclusion: BVT frequently do not mature in patients older than 60 years, which compromises its utility as a primary
access. However, fistulas that mature provide acceptable patency rates, and subsequent conversion to a prosthetic access
is frequently possible. Selective use of BVT might improve the utilization of available access sites. (J Vasc Surg 2004;39:
1043-7.)The primary use of autogenous arteriovenous (AV)
fistulas for chronic hemodialysis access is recommended by
the National Kidney Foundation–Dialysis Outcomes Qual-
ity Initiative (NKF-DOQI) practice guidelines.1 These
guidelines, first published in 1997, were based on an exten-
sive review of the available literature with the goal to make
dialysis both more safe and more cost-effective. One of the
recommendations was to achieve a 50% fistula creation rate
to reach a 40% prevalence. In this country prosthetic grafts
have been used preferentially, likely because of the greater
ease of handling and the ability to be punctured in a
relatively short period of time. Because of NKF-DOQI,
there has been a resurgence of enthusiasm in placing pri-
mary AV fistulas and subsequently more interest in alterna-
tive autogenous fistula techniques. The basilic vein trans-
position arteriovenous fistula (BVT), described in 1976 by
Dagher et al,2 reviewed again in 1986,3 is enjoying a
renewed popularity as surgeons strive to increase autoge-
nous fistula creation rates. Well-described advantages of
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doi:10.1016/j.jvs.2004.01.024using AV fistulas include increased patency rates and de-
creased infection rates compared with prosthetic grafts.4-7
Potential disadvantages include a more technically difficult
surgical procedure, increased length of time to maturation,
and a potentially higher risk of wound complications. This
study reviews our experience with BVT, particularly in
older patients and those with prior access failures, to assess
its maturation rate and patency, as well as to examine its
potential for promoting efficient use of available access
sites.
MATERIAL AND METHODS
All patients undergoing construction of a BVT from
April 1998 to May 2002 were identified by using an office-
based computerized registry. Patients were selected for
basilic vein transposition on the basis of individual surgeon
preference in the absence of a specific institution selection
protocol. Perioperative characteristics such as age, medical
comorbidities, the presence of previous and subsequent
dialysis access procedures, the use of preoperative duplex
vein mapping, procedural complications, and time to first
puncture were tabulated. Patency rates were determined by
using Kaplan-Meier life table methods. Univariate and
logistic regression analyses were then performed by using
the previously mentioned perioperative characteristics to
search for factors affecting maturation and patency. On the
basis of guidelines by the SVS/AAVS Committee on Re-
porting Standards for Arterio-Venous Accesses, the follow-
ing definitions are used: primary patency is the interval from
the time of access placement until any intervention de-1043
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sis, or the time of measurement of patency; primary assisted
patency is the interval from the time of access placement
until access thrombosis including intervening manipulation
designed to maintain the functionality of a patent access;
and secondary patency is the interval from the time of access
placement until access abandonment, thrombosis, or the
time of patency measurement including intervening manip-
ulations designed to re-establish functionality in throm-
bosed access.8
Preoperative duplex imaging. Vein mapping studies
were performed by using HDI 5000 and HDI 3000 duplex
scanners. All studies were performed in an accredited reg-
istered vascular laboratory and reviewed by attending vas-
cular surgeons or radiologists. Superficial veins from the
distal forearm to the axilla were assessed for patency and
measured. Axillary, subclavian, and internal jugular vein
assessment was also routinely performed.
Technique. A longitudinal incision was made over the
medial aspect of the upper arm. The basilic vein was iden-
tified and exposed from the antecubital fossa toward its
junction with the axillary vein. The medial cutaneous
nerves were carefully protected. The brachial artery was
identified just above the antecubital fossa through the same
incision and mobilized. The numerous side branches of the
basilic vein were then isolated, ligated, and divided. The
vein was marked before distal division to prevent twisting.
A subcutaneous tunnel was created laterally on the arm.
The basilic vein was divided distally at the level of the
antecubital fossa, brought over the biceps muscle through
the subcutaneous tunnel, and anastomosed in an end-to-
side fashion to the distal brachial artery. The skin was then
closed in two layers by using absorbable sutures. Routine
intraoperative heparinization was not used.
Statistics. Data were entered into a Microsoft Excel
(Microsoft Corp, Redmond, Wash) spreadsheet for analy-
sis. Statistical analysis was performed by using SAS System,
Release 8.2 (SAS Institute Inc, Cary, NC). The 2 test was
used to determine significance within groups. The Fisher
exact test was used to determine significance between
groups. Kaplan-Meier analysis was used to determine life-
table patency curves. Log-rank testing was used to deter-
mine significance between curves. Binary logistic regression
was performed to analyze factors affecting patency. Re-
ceiver operator characteristic curves were used to determine
age cutoffs. Significance was determined at a P value.05.
RESULTS
A total of 77 patients were identified who underwent
creation of a BVT during the period of review. Of the 77
patients, 21 were lost to follow-up: 8 died during the study
period, and their records were not available for review; 13
had relocated and could not be contacted. This left 56
patients who were available for further study. The clinical
characteristics of the study group are described in Table I.
The characteristics of the excluded patients did not differ
significantly from the remaining patients.Complications. Perioperative complications occurred
after BVT in 5 of 56 patients (9%), including hematomas in
3 and nonfatal cardiac arrest in 1. One patient died during
the perioperative period from an acute myocardial infarc-
tion on postoperative day 15. Two of the patients with
hematomas required operative evacuation. Late ischemic
steal syndrome occurred in 3 patients on late follow-up.
Two patients underwent a distal revascularization/interval
ligation procedure, and another ultimately required a par-
tial finger amputation.
Patency. Maturation time or the average time to first
puncture and use of the fistula was 74 days (range, 12-265
days). Failure to mature sufficiently for access use occurred
in 21 patients (38%). Univariate analysis showed that gen-
der, the presence of diabetes or hypertension, a history of
prior access procedures in the ipsilateral extremity, and the
results of preoperative duplex examinations were not sig-
nificantly associated with maturation failure or decreased
patency. With logistic regression analysis, only age was
shown to correlate with maturation failure. By analyzing
the receiver operator characteristic curves, the best age
cutoff was found to be 60 years of age. Patients 60 years of
age or older were more likely to have fistulas that failed to
mature compared with patients younger than the age of 60
years (odds ratio, 2.5; 95% confidence interval, 1.1-5.5).
Duplex ultrasound imaging was performed in 35 pa-
tients before BVT, as described in Methods. There was no
significant difference in maturation or patency rates be-
tween those patients who did or did not undergo such
imaging. Subgroup analysis in those patients who did un-
dergo imaging also showed no relationship between the
duplex-determined diameter of the basilic vein and matu-
ration or patency rates.
For all BVTs, including those that did not mature,
primary and secondary patencies at 1 year were 35% and
47%, respectively (Fig 1). Considering only those that
matured and were accessed, primary and secondary paten-
cies at 1 year were 53% and 75%, respectively. The only
significant risk factor for graft failure was age older than 60
years (odds ratio, 1.56; 95% confidence interval, 1.1-2.2).
Life-table analysis stratified to age60 years versus age
60 years was also performed. For patients aged60 years,
primary patency and secondary patencies were 53% and
67%, respectively (Fig 2). For patients aged 60 years,
primary and secondary patencies were 18% and 28%, re-
spectively (P  .0028).
Interventions. A total of 21 adjunctive procedures
were performed in 17 patients for failing or failed fistulas;
Table I. Patient characteristics
n %
Mean age (y) 56
Male gender 30 54
Hypertension 44 79
Diabetes 32 57
Primary access 22 39
Preoperative duplex ultrasound scan 35 63
verall
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las, and 8 were performed for occluded fistulas (Table II,
online only).
Subsequent procedures. Of 26 patients who under-
went subsequent access surgery after failure of BVT, 11
(42%) had successful placement of a prosthetic graft in the
ipsilateral arm. Four patients with failed BVT did not
undergo subsequent dialysis access procedures. Fifty per-
cent of patients (13 of 26) received a tunneled or nontun-
neled catheter central venous catheter for dialysis access,
and a more definitive access procedure had not been per-
formed by the end of the study.
Fig 1. O
Fig 2. PDISCUSSION
As dialysis patients become older and long-term sur-
vival rates on dialysis improve, maintenance of viable sites
for dialysis access will become increasingly important. The
NKF-DOQI guidelines have been promulgated in an at-
tempt to improve the efficiency of dialysis including issues
related to vascular access. The creation of autogenous
fistulas has been encouraged because they are associated
with decreased rates of infection and failure and increased
average patency.4-7 However, fistulas are occasionally more
technically challenging to construct and are often involved
patency.
y by age.atenc
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central venous catheters.9,10 BVT has been advocated as an
alternative to a nonautogenous upper arm access. First
described by Dagher et al2 in 1976, the BVT involves
transposing the basilic vein, usually located deep in the
subcutaneous tissues where it is not accessible to simple
percutaneous puncture, into a more superficial location
along the volar surface of the upper arm. This procedure
requires extensive mobilization of the vein, with an anasto-
mosis to the brachial artery just above the antecubital fossa.
Advantages of BVT include the avoidance of prosthetic
material and its attendant risk of infection, the need for only
one vascular anastomosis, and the potential ability to per-
form a nonautogenous AV graft in the same location if the
fistula fails. Major disadvantages include the potential for
vein injury during the required mobilization and wound
complications associated with the extensive dissection, such
as hematoma or injury to the median or cutaneous nerves.
In this report we show lower maturation and patency
rates than in other series on BVT, particularly in older
patients. In our experience, BVT does not perform well in
patients 60 years or older. In this age group, failure oc-
curred in 54% of patients before the fistula was ever ac-
cessed. This higher initial failure rate appears to be the
largest contributor to the lower overall patency rate in older
patients. The reason for a higher incidence of maturation
failure in older patients is unclear. Potential causes include
a higher incidence of atherosclerotic proximal arterial oc-
clusive disease that limits the inflow of blood to the fistula.
Alternatively, there might be a higher incidence of cardiac
or respiratory dysfunction in this age group that diminishes
cardiac output. Unfortunately, in this retrospective review,
we were not able to systematically collect data regarding
these parameters for all patients in this series, and these
hypotheses could not be tested.
Some investigators have shown that preoperative du-
plex ultrasound assessment might improve successful fistula
creation rates.11 We were not able to demonstrate any
significant effect of preoperative mapping on fistula matu-
ration or long-term patency within our sample. This might
be due to selection bias; if preoperative duplex scanning
showed a small-diameter basilic vein, BVT might not have
been attempted. The use of preoperative imaging was not
standardized in this series; therefore, it is not possible to
make any definitive conclusions about its role. However,
the role of duplex scanning is emerging as part of the
routine work-up for vascular access procedures, and it is
recommended by the NKF- DOQI guidelines.
One of the key purported advantages of BVT is the
ability to place a nonautogenous graft subsequently in the
same upper arm location if the fistula should fail. Of 26
fistulas that failed during the study period and underwent a
subsequent dialysis access procedure, 11 ipsilateral upper
arm grafts were subsequently placed. This represents a
substantial number of potential patients who might benefit
from an additional access site. The exact reasons that addi-
tional upper arm grafts were not placed are unknown;
however, it is possible that the presence of central venousstenosis or occlusion could have effectively eliminated the
use of that extremity for future access procedures. How-
ever, because these lesions are being more effectively
treated via endovascular means, utilization of upper arm
sites might improve.
The number of patients on dialysis continues to in-
crease. Contributing to this is the improved survival of
patients on dialysis, as well as the application of dialysis to
younger populations as the transplant pool remains con-
stant. In younger patients, BVT performed significantly
better when compared to older patients. In this subgroup,
the BVT might prove a significant addition to the arma-
mentarium of the vascular surgeon. Younger patients on
hemodialysis are likely to face eventual challenges regarding
access locations because most accesses ultimately will fail.
The use of BVT, especially in younger patients, can effec-
tively increase these options by allowing the use of the
upper arm for two separate access procedures.
CONCLUSION
BVT frequently does not mature sufficiently in patients
older than 60 years, which compromises its utility as a
primary access. However, BVT that matures provides ac-
ceptable 1-year patency rates and frequent successful con-
version to a nonautogenous access after fistula failure,
thereby extending the life of the ipsilateral upper arm as an
access location. Younger patients, who have a prolonged
life expectancy with modern hemodialysis techniques,
might benefit from BVT.
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at www.mosby.com/jvs.DISCUSSIONDr Willis H. Wagner (Los Angeles, Calif). Following the
1976 report by Dr Dagher, the founding members of our practice,
Bud Foran and Dick Treiman, performed many basilic transposi-
tions without the aid of preoperative duplex imaging. Unfortu-
nately, the failure rate was unacceptable and the procedure was
discarded. After dissemination of the Dialysis Outcomes Quality
Initiative guidelines in 1997, we attempted to increase our utiliza-
tion of autogenous fistulas, as did many of the surgeons in this
audience. Because of the advanced age of our dialysis population,
the cephalic vein is frequently not usable. The basilic vein transpo-
sition has now become our most common primary fistula. Since
1998, we have performed 173 basilic transpositions using the same
surgical technique described by Dr Rao. However, our experience
has been very different from these authors. Their 1- and 2-year
primary patency rates were 35% and 15%, respectively. In contrast,
80% of our patients who had basilic transpositions have not re-
quired any further fistula or graft. Only 63% of their patients had
preoperative duplex imaging. We have uniformly used the protocol
recommended by Michael Silva that not only documents the
caliber and the course of the basilic vein but also the adequacy of
the arterial inflow and proximal veins. My first question is, did your
duplex protocol include interrogation of the axillary and subclavian
veins to rule out proximal obstruction and did you establish the
adequacy and caliber of flow in the brachial artery?
Your analysis suggested that the only factor associated with
failure of graft maturation and graft occlusion was age over 59
years. Sixty-one percent of our patients were 60 years of age or over
and the results are identical in patients above and below this cutoff.
This is consistent with a study by Gibson from our colleagues at the
University of Washington (referred to in your paper) that found
that age was not a factor in the patency of 181 basilic transposi-
tions. Surprisingly, the size of the vein on preoperative imaging did
not influence outcome in your series. Do you have any explanation
of why the vein caliber did not seem to influence maturation or
patency? Also, are there other technical factors or intangibles, such
as the experience of the dialysis nurses, that do not lend themselves
to statistical analysis but that could have affected maturation and
patency?
The DOQI work group suggested that allowing a fistula to
mature for 3 or 4 months before use may be ideal. We routinely use
3 months, yet your average time to use was 74 days, including a
minimum of 12 days. Do you feel that any of your fistulas failed due
to early use?
After an occlusion of a basilic transposition, we have usually
placed a new bridge graft in the same arm with polytetrafluoroeth-
ylene. In your presentation, the assisted primary patency curve was
nearly identical to the secondary patency curve. Do you feel there
is merit to aggressive operative or percutaneous thrombectomy
after graft occlusion? We have been reluctant to use chemical
thrombolysis in an occluded fistula due to the risk of bleeding from
multiple prior access sites. Could you share your technique of
percutaneous thrombolysis? In particular, do you use mechanical
or chemical lysis?
Finally, could you explain why 50% of your patients with failed
basilic grafts received only venous catheters for continued access?I’d like to congratulate Dr. Rao for an excellent presentation
of his work. I agree that the transposed basilic vein is a very good
access option. However, I have reservations about excluding its use
in an older dialysis population.
Dr Rajeev K. Rao. Obviously we just spent a little bit of time
discussing preoperative vein mapping strategies and the use in
fistula creation. At our primary institution, we do have a protocol
for preoperative vein mapping. At the other institution we don’t
have that quite in place. Clinical criteria are used more often.
However, we are not routinely interrogating the arterial inflow on
these patients and merely have been using clinical criteria. Cer-
tainly, as mentioned by Dr Wagner, Silva et al showed that the use
of measuring the radial artery and assessing brachial artery inflow
has been one of their adjunctive therapies to increase their rate of
fistula use. It is certainly something that could be suggested. We do
evaluate the complete venous outflow. However, once again, one
the potential weaknesses of our experience is that we do not have a
rigid preoperative venous mapping protocol, and many patients
underwent just simple surgical exploration prior to their basilic
vein transposition.
As I mentioned, there doesn’t seem to be a trend with the
increase in venous size that we noted. I don’t personally know of
any literature that does talk about the size of the basilic vein per se;
however, that doesn’t mean it isn’t out there. Once again we don’t
really use that as criteria to determine whether or not we are going
to attempt a fistula.
One of the other things mentioned is that the majority of our
patients are dialyzed at outside centers, and often the primary
access when the fistulas are used is determined by the dialysis center
and not necessarily decided on by the vascular surgeon in question.
That is why there is an extreme variability in the maturation time or
the time that we use to access these fistulas. There is one there that
was 12 days as mentioned. Incidentally, I was unable to find out
why that fistula was accessed 12 days after surgery. However, I do
know that that particular fistula did last to the end of the study,
which was over a year, so I really don’t have an explanation. You
would expect that fistula to be the one to fail. We don’t control
within our institution; within our institution we are able to control
and get some experience with the dialysis nursing; however, since
there are approximately 15 to 20 dialysis centers that these patients
are seen at, I can’t comment on whether or not there is technical
inadequacy with dialysis access.
There was an initial feeling that the basilic vein was a thin vein,
that it would become aneurysmal and that these technical things
would cause problems with access. Once again, I did not see that
when I reviewed our experience. There was very little aneurysmal
dilatation noted and there weren’t significant bleeding complica-
tions associated with access.
Part of the secondary procedures that we used, primarily for an
occluded graft, was a combination of pharmaco and mechanical
lysis—lyse and go technique if you will—where we instill a throm-
bolytic agent immediately followed by balloon maceration of any
thrombus within the fistula, and almost always we have found that
there is some sort of stenotic lesion within the venous side of the
fistula that is treated at the same time.
